VOR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	138 367
Gjennomsnittsvolum	336 337
Markedsverdi	122.79M
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.030
ATR14	$0.00500 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Ang Robert	Sell	2 751	Common Stock
2024-05-01	Attar Eyal C.	Sell	1 146	Common Stock
2024-05-01	Jorgensen Nathan D.	Sell	917	Common Stock
2024-05-01	Chakraborty Tirtha	Sell	985	Common Stock
2024-04-30	Namouni Fouad	Buy	60 000	Stock Option (right to buy)

INSIDER POWER
97.38
Last 98 transactions
Buy: 33 390 275 \| Sell: 91 899 640

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.39 (neutral)

Signal:(53.375) Neutral

Vor Biopharma Inc. Korrelasjon

10 Mest positive korrelasjoner
BNIXU	0.936
NUTX	0.88
WEN	0.85
GLMD	0.847
SBEAU	0.833
ATIF	0.816
BGNE	0.806
FRAF	0.801
KTRA	0.801

10 Mest negative korrelasjoner
WTER	-0.873
HOOK	-0.827
SLDP	-0.82
GSM	-0.816
MTEK	-0.815
PMD	-0.815
GRAY	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vor Biopharma Inc. Korrelasjon - Valuta/Råvare

0.23
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.42
( neutral )

-0.04
( neutral )

Vor Biopharma Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3.49M (0.00 %)
EPS:	$-1.750

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3.49M (0.00 %)
EPS:	$-1.750

FY	2022
Omsetning:	$0
Bruttogevinst:	$-8.96M (0.00 %)
EPS:	$-2.29

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Vor Biopharma Inc.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sanntidsoppdatering for Vor Biopharma Inc. [VOR]

Upcoming Earnings Alert